Advertisement D3 Pharma, Encap to advance Plenachol licensing program - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

D3 Pharma, Encap to advance Plenachol licensing program

D3 Pharma and Encap Drug Delivery are continuing partnership to advance the commercial manufacturing and product licensing program for Plenachol.

Plenachol is proprietary high-dose oral vitamin D3 product for the treatment of vitamin D deficiency and insufficiency.

The patented liquid-filled capsule formulation was developed in conjunction with Encap and is available at three dose-strengths 20,000, 40,000 and 100,000 international units.

Plenachol, which is free from animal derived excipients and peanut constituents, will continue to be made available as a Specials product during the pre-license phase through Encap.